XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION
 9 Months Ended
Jul. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2023 and 2022 and as of July 31, 2023 and October 31, 2022, in thousands:

 

   2023   2022   2023   2022 
  

For the Three Months Ended

July 31,

  

For the Nine Months Ended

July 31,

 
   2023   2022   2023   2022 
Net Loss:                    
CAR-T Therapeutics  $(1,091)  $(965)  $(2,999)  $(3,975)
Cancer Vaccines   (1,390)   (903)   (3,261)   (3,684)
Anti-Viral Therapeutics   (62)   (904)   (960)   (2,565)
Other   (5)   (3)   11    (18)
Total  $ (2,548)  $(2,775)  $(7,209)  $(10,242)
                     
Total operating costs and expenses  $2,844   $2,797   $8,170   $10,266 
Less non-cash share-based compensation   (1,217)   (1,446)   (3,507)   (5,546)
Operating costs and expenses
excluding non-cash share-based
compensation		  $1,627   $1,351   $4,663   $4,720 
 Operating costs and expenses excluding
non-cash share-based compensation:		                    
CAR-T Therapeutics  $713   $421   $1,930   $1,823 
Cancer Vaccines   855    376    1,966    1,571 
Anti-Viral Therapeutics   55    552    572    1,312 
Other   4    2    195    14 
Total  $1,627   $1,351   $4,663   $4,720 

 

   July 31, 2023   October 31, 2022 
Total assets:          
CAR-T Therapeutics  $11,640   $16,921 
Cancer Vaccines   13,968    9,442 
Anti-Viral Therapeutics   898    3,811 
Other   72    238 
Total  $26,578   $30,412 

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000 for the nine months ended July 31, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.